Composition comprising N-acetylcysteine and / or microencapsulated gastroprotective lysozyme in combination with probiotic bacteria capable of repairing the gastric barrier effect lost during gastric acidity drug treatment
- 专利权人:
- ジョヴァンニ・モーニャ
- 发明人:
- ジョヴァンニ・モーニャ
- 申请号：
- JP2014529081
- 公开号：
- JP6130379B2
- 申请日:
- 2012.09.10
- 申请国别(地区):
- JP
- 年份:
- 2017
- 代理人:
- 摘要：
- The present invention refers to a composition comprising N-acetylcysteine and/or lysozyme； or N-acetylcysteine and microencapsulated gastroprotected lysozyme with probiotic bacteria for use in the pharmacological treatment of gastric hyperacidity. Said composition is capable of restoring the stomach's own barrier effect, which is lost during the pharmacological treatment of gastric hyperacidity, and of minimising the secondary effects due to said pharmacological treatment.
- 来源网站：
- 中国工程科技知识中心
相关发明人
相关专利
- COMPOSITION COMPRISING N ACETYLCYSTEINE AND/OR MICROENCAPSULATED GASTROPROTECTED LYSOZYME IN ASSOCIATION WITH PROBIOTIC BACTERIA CAPABLE OF RESTORING THE STOMACH S OWN BARRIER EFFECT WHICH IS LOST DURING THE PHARMACOLOGICAL TREATMENT OF GASTRIC HYPERACIDITY
- COMPOSITION COMPRISING N-ACETYLCYSTEINE AND/OR MICROENCAPSULATED GASTROPROTECTED LYSOZYME IN ASSOCIATION WITH PROBIOTIC BACTERIA CAPABLE OF RESTORING THE STOMACH'S OWN BARRIER EFFECT WHICH IS LOST DURING THE PHARMACOLOGICAL TREATMENT OF GASTRIC HYPERACIDITY
- Composition comprising N-acetylcysteine and/or microencapsulated gastroprotected lysozyme in association with probiotic bacteria capable of restoring the stomach's own barrier effect which is lost during the pharmacological treatment of gastric hyperacidity
- composition comprising n - n-acetylcysteine and / or lysozyme microincapsulato gastroprotetto in combination with probiotic bacteria capable of restoring the barrier effect of the stomach which is lost during the treatment of the
- A composition comprising n-acetylcysteine and / or microencapsulated gastroprotected lysozyme in combination with probiotic bacteria capable of restoring the barrier effect of the stomach itself which is lost during the pharmacological treatment of gastric hyperacidity.
